---
title: "Embolic Stroke and DOAC Failure in Libman-Sacks Endocarditis with Antiphospholipid Syndrome"
id: "pubmed-43058350"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-43058350"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/43058350/"
doi: "10.1007/s00296-026-06331-w"
published_at: "2026-11-20T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Embolic Stroke and DOAC Failure in Libman-Sacks Endocarditis with Antiphospholipid Syndrome
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-43058350
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/43058350/)
- **DOI:** [10.1007/s00296-026-06331-w](https://doi.org/10.1007%2Fs00296-026-06331-w)
- **Published At:** 2026-11-20T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- A 37-year-old man with obesity, type 2 diabetes, chronic kidney disease and recurrent unprovoked deep vein thrombosis developed multiple **embolic strokes** while taking **rivaroxaban**; transoesophageal echocardiography identified a sessile aortic valve mass. - Repeated blood cultures and 18F-FDG PET-CT were negative; lupus anticoagulant was the only antiphospholipid antibody detected in the index patient, consistent with probable **antiphospholipid syndrome** (APS). - The patient was switched from a DOAC to low-molecular-weight heparin and acenocoumarol; the valve mass was surgically excised and histology showed an organised fibrinous thrombotic vegetation, although papillary fibroelastoma could not be excluded. - Using CABARET recommendations, investigators searched MEDLINE/PubMed, Scopus, Web of Science and DOAJ for reports from January 2020 to September 2026 and identified 62 case reports/series (63 patients) and four cohort studies for synthesis. - Across the pooled reports median age was 40 years (range 19–78); 22/60 (37%) were men; 34/63 (54%) had primary APS and 6/63 (10%) had catastrophic APS when reported. - Antibody profiles (when reported) included triple-positive status in 22/39 patients (56%) and lupus-anticoagulant-only in 4/39 (10%). - Valve distribution: mitral involvement in 41/62 (66%), aortic in 19/62 (31%), tricuspid in 7/62 (11%). - Clinical consequences were frequent: ischaemic stroke in 29/63 (46%) and heart failure or severe valve dysfunction in 31/63 (49%). - Of 16 patients anticoagulated at diagnosis, 10 (63%) were receiving a **DOAC**; valve intervention occurred in 35/63 (56%) and 4/63 (6%) died. - The authors reported that LSE should be considered in APS patients with embolic events, especially those on **DOACs**, but emphasized that available evidence remains observational and derived largely from case reports and small cohorts.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/43058350/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43058350%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/43058350/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/43058350/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/43058350/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/43058350/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/43058350/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/43058350/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43058350%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43058350%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/43058350/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43058350/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43058350/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/43058350/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43058350/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/43058350/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/43058350/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/43058350/#conflict-of-interest) * [ References ](https://pubmed.ncbi.nlm.nih.gov/43058350/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/43058350/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/43058350/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/43058350/#substances) Title & authors Abstract Conflict of interest statement References Publication types MeSH terms Substances Review Rheumatol Int Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Rheumatol+Int%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Rheumatol+Int%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) . 2026 Nov 20;46(12):315. doi: 10.1007/s00296-026-06331-w. # Embolic stroke and breakthrough thrombosis on direct oral anticoagulants in Libman-Sacks endocarditis associated with antiphospholipid syndrome: a case-based review [Foteini Angelopoulou](https://pubmed.ncbi.nlm.nih.gov/?term=Angelopoulou+F&cauthor_id=43058350)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43058350/#full-view-affiliation-1 "Department of Cardiology, General Hospital of Patras "St Andrews", Patras, Greece. fwteiniag@gmail.com."), [Dionysia Stathopoulou](https://pubmed.ncbi.nlm.nih.gov/?term=Stathopoulou+D&cauthor_id=43058350)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43058350/#full-view-affiliation-2 "Department of Cardiology, General Hospital of Patras "St Andrews", Patras, Greece."), [Konstantinos Vlachogiorgos](https://pubmed.ncbi.nlm.nih.gov/?term=Vlachogiorgos+K&cauthor_id=43058350)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43058350/#full-view-affiliation-2 "Department of Cardiology, General Hospital of Patras "St Andrews", Patras, Greece."), [Georgios Almpanis](https://pubmed.ncbi.nlm.nih.gov/?term=Almpanis+G&cauthor_id=43058350)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43058350/#full-view-affiliation-2 "Department of Cardiology, General Hospital of Patras "St Andrews", Patras, Greece.") Affiliations Expand ### Affiliations * 1 Department of Cardiology, General Hospital of Patras "St Andrews", Patras, Greece. fwteiniag@gmail.com. * 2 Department of Cardiology, General Hospital of Patras "St Andrews", Patras, Greece. * PMID: **43058350** * DOI: [ 10.1007/s00296-026-06331-w ](https://doi.org/10.1007/s00296-026-06331-w) Item in Clipboard Review # Embolic stroke and breakthrough thrombosis on direct oral anticoagulants in Libman-Sacks endocarditis associated with antiphospholipid syndrome: a case-based review Foteini Angelopoulou et al. Rheumatol Int. 2026. Show details Display options Display options Format Abstract PubMed PMID Rheumatol Int Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Rheumatol+Int%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Rheumatol+Int%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) . 2026 Nov 20;46(12):315. doi: 10.1007/s00296-026-06331-w. ### Authors [Foteini Angelopoulou](https://pubmed.ncbi.nlm.nih.gov/?term=Angelopoulou+F&cauthor_id=43058350)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43058350/#short-view-affiliation-1 "Department of Cardiology, General Hospital of Patras "St Andrews", Patras, Greece. fwteiniag@gmail.com."), [Dionysia Stathopoulou](https://pubmed.ncbi.nlm.nih.gov/?term=Stathopoulou+D&cauthor_id=43058350)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43058350/#short-view-affiliation-2 "Department of Cardiology, General Hospital of Patras "St Andrews", Patras, Greece."), [Konstantinos Vlachogiorgos](https://pubmed.ncbi.nlm.nih.gov/?term=Vlachogiorgos+K&cauthor_id=43058350)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43058350/#short-view-affiliation-2 "Department of Cardiology, General Hospital of Patras "St Andrews", Patras, Greece."), [Georgios Almpanis](https://pubmed.ncbi.nlm.nih.gov/?term=Almpanis+G&cauthor_id=43058350)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43058350/#short-view-affiliation-2 "Department of Cardiology, General Hospital of Patras "St Andrews", Patras, Greece.") ### Affiliations * 1 Department of Cardiology, General Hospital of Patras "St Andrews", Patras, Greece. fwteiniag@gmail.com. * 2 Department of Cardiology, General Hospital of Patras "St Andrews", Patras, Greece. * PMID: **43058350** * DOI: [ 10.1007/s00296-026-06331-w ](https://doi.org/10.1007/s00296-026-06331-w) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Libman-Sacks endocarditis (LSE) is a characteristic cardiac manifestation of antiphospholipid syndrome (APS), but its presentation and management in the era of direct oral anticoagulants (DOACs) are poorly characterised. We describe a 37-year-old man with obesity, type 2 diabetes, chronic kidney disease and recurrent unprovoked deep vein thrombosis who developed multiple embolic strokes while taking rivaroxaban. Transoesophageal echocardiography showed a sessile aortic valve mass; repeated blood cultures and 18F-FDG PET-CT were negative, and lupus anticoagulant was the only antiphospholipid antibody detected (probable APS). He was switched to low-molecular-weight heparin and acenocoumarol and the mass was excised; histology showed an organised fibrinous thrombotic vegetation, although papillary fibroelastoma could not be fully excluded. Following the CABARET recommendations, we searched MEDLINE/PubMed, Scopus, Web of Science and DOAJ for reports published between January 2020 and September 2026 and included 62 case reports/series (63 patients) and four cohort studies. Median age was 40 years (range 19-78); 22/60 patients (37%) were men; 34/63 (54%) had primary APS and 6 (10%) catastrophic APS. When reported, the antibody profile was triple-positive in 22/39 (56%) and lupus-anticoagulant-only in 4/39 (10%). The mitral valve was involved in 41/62 (66%), the aortic in 19/62 (31%) and the tricuspid in 7/62 (11%). Ischaemic stroke occurred in 29/63 (46%) and heart failure or severe valve dysfunction in 31/63 (49%). Of 16 patients anticoagulated at diagnosis, 10 (63%) were receiving a DOAC. Valve intervention was performed in 35/63 (56%) and 4/63 (6%) died. LSE should be sought in patients with APS who have embolic events, particularly while on DOACs; the evidence remains observational. **Keywords:** Antiphospholipid syndrome; Endocarditis, non-infective; Factor Xa inhibitors; Heart valve diseases; Ischemic stroke; Lupus coagulation inhibitor. © 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declarations. Conflict of interest: The authors declare that they have no competing interests. Ethical approval: Not required; according to the CABARET recommendations, case-based reviews reporting one to three patients without hypothesis testing may be exempted from ethical approva. Consent for publication: Written informed consent for publication of this case-based review, including clinical data and images, was obtained from the patient; the signed form is available to the Editor on request. Congress presentation: No part of this work has been presented at a scientific meeting or published as a congress abstract. Use of artificial intelligence: Claude (Anthropic) was used by FA to assist in drafting and language editing of the original manuscript. During revision on 28 September 2026, Claude Opus 5.5 (Anthropic; model identifier "claude-opus-5-5"), accessed through the Claude desktop application, was used to run and document the PubMed and DOAJ searches and to draft the data-extraction table. The authors checked every AI-generated or AI-edited passage, verified all extracted data and references against the original sources, and take full responsibility for the content. Disclaimer: No part of this case-based review has been copied from other sources or published elsewhere. AI-assisted drafting and editing were limited to the uses disclosed above; all scientific content, data interpretation and conclusions are those of the authors. ## References 1. 1. Libman E, Sacks B (1924) A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 33(6):701–737. - [DOI](https://doi.org/10.1001/archinte.1924.00110300044002) 2. 1. Hojnik M, George J, Ziporen L, Shoenfeld Y (1996) Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93(8):1579–87. - [DOI](https://doi.org/10.1161/01.cir.93.8.1579) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/8608627/) 3. 1. Zuily S, Regnault V, Selton-Suty C, Eschwège V, Bruntz JF, Bode-Dotto E et al (2011) Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation 124(2):215–24. - [DOI](https://doi.org/10.1161/circulationaha.111.028522) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/21690492/) 4. 1. Ahmed O, King NE, Qureshi MA, Choudhry AA, Osama M, Zehner C et al (2025) Non-bacterial thrombotic endocarditis: a clinical and pathophysiological reappraisal. Eur Heart J 46(3):236–249. - [DOI](https://doi.org/10.1093/eurheartj/ehae788) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/39565324/) 5. 1. Lenz CJ, Mankad R, Klarich K, Kurmann R, McBane RD (2020) Antiphospholipid syndrome and the relationship between laboratory assay positivity and prevalence of non-bacterial thrombotic endocarditis: a retrospective cohort study. J Thromb Haemost 18(6):1408–1414. - [DOI](https://doi.org/10.1111/jth.14798) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/32180317/) Show all 109 references ## Publication types * Case Reports Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Case+Reports%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Case+Reports) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) ## MeSH terms * Administration, Oral Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Administration%2C+Oral%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Administration%2C+Oral) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) * Adult Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adult%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adult) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) * Anticoagulants / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anticoagulants%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Anticoagulants) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) * Antiphospholipid Syndrome* / complications Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antiphospholipid+Syndrome%2Fcomplications%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antiphospholipid+Syndrome) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) * Embolic Stroke* / etiology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Embolic+Stroke%2Fetiology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Embolic+Stroke) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) * Endocarditis* / complications Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Endocarditis%2Fcomplications%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Endocarditis) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) * Endocarditis* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Endocarditis%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Endocarditis) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) * Endocarditis* / etiology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Endocarditis%2Fetiology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Endocarditis) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) * Factor Xa Inhibitors* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Factor+Xa+Inhibitors%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Factor+Xa+Inhibitors) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) * Male Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Male%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Male) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43058350/) ## Substances * Anticoagulants Actions * [ Search in PubMed ](https://pubmed.ncbi.n
## Related Clinical Research

- [ZEUS trial: IL-6 blocker ziltivekimab lowered inflammation but did not cut major CV events](https://medichelpline.com/clinical-feed/aha-news-1-researchers-say-inflammation-as-a-treatment-target-still-important-despite.md)
- [Comparing BMI, Waist Circumference, and BRI for Predicting ASCVD, AF, and Mortality in 1.2M Koreans](https://medichelpline.com/clinical-feed/plos-one-14-prognostic-associations-of-anthropometric-indices-with-major-health-outcomes-a.md)
- [New CKM Health Education Resources Enhance Patient Care for Cardiovascular and Kidney Risks](https://medichelpline.com/clinical-feed/aha-news-2-new-cardiovascular-kidney-metabolic-ckm-health-education-helps-clinicians-turn.md)
- [Lifestyle Changes May Help Prevent Multimorbidity In Prediabetes](https://medichelpline.com/clinical-feed/medical-news-today-23-diet-weight-loss-and-150-minutes-of-exercise-may-protect-against-chronic.md)
- [Moving Forward: The Future of GLP-1 Therapies](https://medichelpline.com/clinical-feed/endocrine-news-18-moving-forward-the-future-of-glp-1-therapies.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.